BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)